HRP20200673T1 - Makrociklički inhibitori mcl1 za liječenje raka - Google Patents
Makrociklički inhibitori mcl1 za liječenje raka Download PDFInfo
- Publication number
- HRP20200673T1 HRP20200673T1 HRP20200673TT HRP20200673T HRP20200673T1 HR P20200673 T1 HRP20200673 T1 HR P20200673T1 HR P20200673T T HRP20200673T T HR P20200673TT HR P20200673 T HRP20200673 T HR P20200673T HR P20200673 T1 HRP20200673 T1 HR P20200673T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid form
- compound
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 7
- 201000011510 cancer Diseases 0.000 title claims 5
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150094281 mcl1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000007787 solid Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000004807 desolvation Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (24)
1. Spoj naznačen time što je 17-kloro-5,13,14,22-tetrametil-28-oksa-2,9-ditia-5,6,12,13,22-pentaazaheptaciklo[27.7.1.14,7.011,15.016,21.020,24.030,35]oktatriakonta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridekaen-23-karboksilna kiselina (Formula I)
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1.
3. Farmaceutski prihvatljiva sol spoja prema patentnom zahtjevu 1.
4. Spoj prema patentnom zahtjevu 1, naznačen time što spoj Formule I ima strukturu (Ra)-17-kloro-5,13,14,22-tetrametil-28-oksa-2,9-ditia-5,6,12,13,22-pentaazaheptaciklo[27.7.1.14,7.011,15.016,21.020,24.030,35]oktatriakonta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridekaen-23-karboksilna kiselina (Formula II)
[image]
ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema patentnom zahtjevu 4.
6. Farmaceutski prihvatljiva sol spoja prema patentnom zahtjevu 4.
7. Spoj prema patentnom zahtjevu 1, naznačen time što spoj Formule I ima strukturu (Sa)-17-kloro-5,13,14,22-tetrametil-28-oksa-2,9-ditia-5,6,12,13,22-pentaazaheptaciklo[27.7.1.14,7.011,15.016,21.020,24.030,35]oktatriakonta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridekaen-23-karboksilna kiselina (Formula III)
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema patentnom zahtjevu 7.
9. Farmaceutski prihvatljiva sol spoja prema patentnom zahtjevu 7.
10. Spoj, ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od patentnih zahtjeva 1-9, naznačen time što je u kristalnom obliku.
11. Kruti oblik (Ra)-17-kloro-5,13,14,22-tetrametil-28-oksa-2,9-ditia-5,6,12,13,22-pentaazaheptaciklo[27.7.1.14,7.011,15.016,21.020,24.030,35]oktatriakonta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridekaen-23-karboksilna kiselina (Formula II)
[image]
ili njegova farmaceutski prihvatljiva sol.
12. Kruti oblik prema patentnom zahtjevu 11, naznačen time što kruti oblik je Oblik A monohidrata (Ra)-17-kloro-5,13,14,22-tetrametil-28-oksa-2,9-ditia-5,6,12,13,22-pentaazaheptaciklo[27.7.1.14,7.011,15.016,21.020,24.030,35]oktatriakonta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridekaen-23-karboksilne kiseline koji ima XRPD uzorak koji obuhvaća najmanje jedan vrh izražen kao 2Θ (±0.2°) odabran od 5,4°, 7,0°, 8,4°, 10,7°, 12,5°, 13,1°, 14,4°, 15,1°, 15,6°, 17,1° i 18,2°.
13. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima XRPD uzorak koji obuhvaća najmanje jedan vrh izražen kao 2θ (±0.2°) odabran od 7,0°, 8,4° i 12,5°.
14. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima XRPD uzorak uglavnom sličan kao na Slici 1.
15. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima DSC termogram koji obuhvaća endotermu s nastupom desolvacije na oko 121 °C i maksimumom na oko 152 °C.
16. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima DSC termogram koji obuhvaća endotermu s nastupom taljenja/ raspadanja na oko 181 °C i maksimumom na oko 194 °C.
17. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima DSC uzorak uglavnom sličan Slici 2.
18. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima TGA termogram koji pokazuje gubitak mase od oko 4% pri zagrijavanju od oko 25 °C do oko 160 °C.
19. Kruti oblik prema patentnom zahtjevu 12, naznačen time što kruti oblik ima TGA uzorak uglavnom sličan kao na Slici 2.
20. Farmaceutski pripravak naznačen time što sadrži spoj prema bilo kojem od zahtjeva 1-11, ili njegova farmaceutski prihvatljiva sol i farmaceutski pomoćno sredstvo, nosač ili razrjeđivač.
21. A spoj prema bilo kojem od zahtjeva 1-19, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za upotrebu u liječenju raka.
22. Spoj za uporabu prema patentnom zahtjevu 21, naznačen time što rak je hematološki karcinom ili solidni tumor.
23. Spoj za uporabu prema patentnom zahtjevu 22, naznačen time što je hematološki karcinom odabran od akutne mijeloidne leukemije, multiplog mijeloma, limfoma plaštenih stanica, kronične limfocitne leukemije, difuznog velikog B staničnog limfoma, Burkittovog limfoma i folikularnog limfoma.
24. Spoj za uporabu prema patentnom zahtjevu 22, naznačen time što je solidni tumor odabran od karcinoma pluća ne-malih stanica, karcinoma pluća malih stanica, raka dojke, neuroblastoma, raka prostate, melanoma, raka gušterače, raka maternice, raka endometrija i raka debelog crijeva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662326156P | 2016-04-22 | 2016-04-22 | |
EP17720720.6A EP3445767B1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200673T1 true HRP20200673T1 (hr) | 2020-07-10 |
Family
ID=58664658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200673TT HRP20200673T1 (hr) | 2016-04-22 | 2020-04-28 | Makrociklički inhibitori mcl1 za liječenje raka |
Country Status (37)
Country | Link |
---|---|
US (4) | US9840518B2 (hr) |
EP (1) | EP3445767B1 (hr) |
JP (1) | JP6894449B2 (hr) |
KR (1) | KR102388208B1 (hr) |
CN (1) | CN109071566B (hr) |
AR (1) | AR108301A1 (hr) |
AU (1) | AU2017252222B2 (hr) |
BR (1) | BR112018070677B1 (hr) |
CA (1) | CA3020378A1 (hr) |
CL (1) | CL2018002410A1 (hr) |
CO (1) | CO2018008759A2 (hr) |
CR (1) | CR20180499A (hr) |
CY (1) | CY1123186T1 (hr) |
DK (1) | DK3445767T3 (hr) |
DO (1) | DOP2018000222A (hr) |
EA (1) | EA036551B1 (hr) |
ES (1) | ES2791319T3 (hr) |
HR (1) | HRP20200673T1 (hr) |
HU (1) | HUE049591T2 (hr) |
IL (1) | IL262237B (hr) |
LT (1) | LT3445767T (hr) |
MA (1) | MA44721B1 (hr) |
ME (1) | ME03729B (hr) |
MX (1) | MX2018012711A (hr) |
NI (1) | NI201800093A (hr) |
PE (1) | PE20181803A1 (hr) |
PH (1) | PH12018502227A1 (hr) |
PL (1) | PL3445767T3 (hr) |
PT (1) | PT3445767T (hr) |
RS (1) | RS60257B1 (hr) |
SG (1) | SG11201805838UA (hr) |
SI (1) | SI3445767T1 (hr) |
SV (1) | SV2018005742A (hr) |
TN (1) | TN2018000319A1 (hr) |
TW (1) | TWI742074B (hr) |
WO (1) | WO2017182625A1 (hr) |
ZA (1) | ZA201807766B (hr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3782636B1 (en) | 2016-02-04 | 2024-05-15 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
US11708391B2 (en) | 2016-02-04 | 2023-07-25 | The Johns Hopkins University | Rapaglutins, novel inhibitors of GLUT and use thereof |
US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
CO2018008759A2 (es) | 2016-04-22 | 2018-09-20 | Astrazeneca Ab | Inhibidores de mcl-1 y métodos de uso de los mismos |
EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Mcl-1抑制劑及其使用方法 |
TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成mcl-1抑制劑之方法 |
BR112020003180A2 (pt) | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
WO2019035899A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
EP3710450A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
US11401278B2 (en) | 2017-11-17 | 2022-08-02 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
EP3710449B1 (en) * | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
JP7234250B2 (ja) * | 2017-11-17 | 2023-03-07 | バイエル アクチェンゲゼルシャフト | 置換大環状インドール誘導体 |
UY37972A (es) * | 2017-11-17 | 2019-06-28 | Bayer Pharma AG | Derivados de indol macrocíclicos sustituidos con cloro |
US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
US20220041623A1 (en) | 2018-09-30 | 2022-02-10 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method thereof and application thereof in medicine |
TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
US20220396587A1 (en) * | 2019-01-23 | 2022-12-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
SG11202109367WA (en) * | 2019-03-08 | 2021-09-29 | Zeno Management Inc | Macrocyclic compounds |
TW202106693A (zh) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 |
TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體-藥物結合物及使用方法 |
MX2021015770A (es) * | 2019-06-21 | 2022-04-12 | Janssen Pharmaceutica Nv | Inhibidores macrociclicos de mcl-1. |
MX2022000390A (es) | 2019-07-09 | 2022-02-10 | Janssen Pharmaceutica Nv | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. |
US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
MX2022006179A (es) | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de indol como inhibidores de mcl-1. |
EP4061820A1 (en) | 2019-11-21 | 2022-09-28 | Janssen Pharmaceutica NV | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
CN115052880A (zh) * | 2019-12-18 | 2022-09-13 | 芝诺管理公司 | 大环化合物 |
CA3168355A1 (en) | 2020-02-21 | 2021-08-26 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as inhibitors of mcl-1 |
WO2021197295A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
EP4157852A1 (en) * | 2020-05-29 | 2023-04-05 | JANSSEN Pharmaceutica NV | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
JP2023530985A (ja) | 2020-06-19 | 2023-07-20 | ヤンセン ファーマシューティカ エヌ.ベー. | Mcl-1の阻害剤としてのn結合大環状7-(ピラゾール-5-イル)-インドール誘導体 |
BR112022025631A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1 |
US20230250109A1 (en) | 2020-07-08 | 2023-08-10 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
AU2021385349A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
AU2021403616A1 (en) | 2020-12-17 | 2023-08-03 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
MX2023009475A (es) | 2021-02-12 | 2023-08-22 | Janssen Pharmaceutica Nv | Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. |
WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
US8445679B2 (en) * | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
PT2379580E (pt) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Novos agentes antibacterianos para o tratamento de infecções por bactérias gram positivas |
JP5731538B2 (ja) * | 2009-12-23 | 2015-06-10 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Crth2モジュレーター |
MX349366B (es) * | 2011-05-19 | 2017-07-26 | Centro Nac De Investigaciones Oncologicas (Cnio) | Compuestos novedosos. |
US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
EP3105236B1 (en) * | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
CN106456602B (zh) | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
AU2015243585B2 (en) * | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
CO2018008759A2 (es) | 2016-04-22 | 2018-09-20 | Astrazeneca Ab | Inhibidores de mcl-1 y métodos de uso de los mismos |
-
2017
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200673T1 (hr) | Makrociklički inhibitori mcl1 za liječenje raka | |
JP2019514863A5 (hr) | ||
WO2016160617A3 (en) | Inhibitors of cyclin-dependent kinases | |
MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
HRP20161203T1 (hr) | Novi derivati tienopirimidina, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
JP2013522292A5 (hr) | ||
PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
EP3828186A3 (en) | Pyrimidinones as factor xia inhibitors | |
PH12015501199A1 (en) | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 | |
WO2014036015A1 (en) | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases | |
NZ629684A (en) | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one | |
PE20140002A1 (es) | Proceso de elaboracion para derivados de pirimidina | |
CN101827819A (zh) | 阿片样物质酰胺季铵盐 | |
MX2016004964A (es) | Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo. | |
JP2012504628A5 (hr) | ||
MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
JP2019519512A5 (hr) | ||
Singh et al. | Design, regioselective synthesis and cytotoxic evaluation of 2-aminoimidazole–quinoline hybrids against cancer and primary endothelial cells | |
JP2012526766A5 (hr) | ||
MX2016010436A (es) | Compuestos de pirazolona y usos de los mismos. | |
DK2061452T3 (da) | Anvendelse af koffeinsyre og derivater deraf mod cancer | |
JP2019532919A5 (hr) | ||
AR116880A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm | |
CA3126738A1 (en) | Preparation method for morpholinquinazoline compound and midbody thereof | |
SI3174881T1 (en) | (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases |